Rationale: Diagnosis of asthma is based on the presence of symptoms (clinical diagnosis) supported by lung function measurements, such as forced expiratory volume in one second (FEV1) and peak expiratory flow (PEF) variability. Recently, it has been reported that the forced expiratory flow at 25-75 of the pulmonary volume might be considered as a possible marker of early bronchial impairment in patients with allergic rhinitis.
Objectives: The aim of this retrospective study was to identify the most reliable spirometric parameter for the follow up of intermittent allergic asthma.
Methods: Data from 108 outpatients with intermittent allergic asthma was studied. The spirometric parameters before and after 1 week of short aerosol therapy were analyzed. Patients were divided into three groups according to basal FEV1 values: those with all spirometric values normal, those with reduced FEV1 and those with normal FEV1 but reduced FEF75.
Results: There was a good correlation between the spirometric parameters analysed. FEF75 showed a greater significant reduction than FEV1 and PEF. Moreover, 26 of 38 patients with normal FEV1 (68 %) showed a reduction in FEF75. No significant differences were observed between FEV1 and PEF. After short aerosol therapy, FEV1 improved in 93% of patients, but many (61%) still had a reduced FEF75 value, thus the correlation between the two parameters decreased (from r= 0.68 to r = 0.40).
Conclusions: On the basis of these observations, FEF75 should be reconsidered a usefull spirometric parameter for allergic asthma follow up.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effects of acetazolamide on exercise performance in patients with COPD going to high altitude: randomised controlled trial.
ERJ Open Res
January 2025
Department of Respiratory Medicine, University Hospital of Zurich, Zurich, Switzerland.
Background: In patients with COPD, preventive treatment with acetazolamide reduces adverse health effects during altitude travel. We investigated whether preventive acetazolamide treatment modifies exercise performance in COPD patients going to high altitude.
Methods: In this randomised, double-blind trial, lowlanders with COPD, forced expiratory volume in 1 s (FEV) 40-80% predicted, were assigned to acetazolamide (375 mg per 24 h) or placebo treatment starting 24 h before ascent and while staying at 3100 m.
Role of pulmonary rehabilitation in extracellular matrix protein expression in vastus lateralis muscle in atrophic and nonatrophic patients with COPD.
ERJ Open Res
January 2025
Faculty of Health and Life Sciences, Northumbria University Newcastle, Newcastle upon Tyne, UK.
Background: In response to exercise-based pulmonary rehabilitation (PR), the type of muscle fibre remodelling differs between COPD patients with peripheral muscle wasting (atrophic patients with COPD) and those without wasting (nonatrophic patients with COPD). Extracellular matrix (ECM) proteins are major constituents of the cell micro-environment steering cell behaviour and regeneration. We investigated whether the composition of ECM in atrophic compared to nonatrophic patients with COPD differs in response to PR.
View Article and Find Full Text PDFCharacterization of diffuse lung function in children with pneumonia.
Front Pediatr
January 2025
Pediatric Respiratory Medicine Department, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Background: infection accounts for a high proportion of community-acquired pneumonia and the incidence rate of severe pneumonia (MPP) has increased year by year. This study investigated the changes in lung diffusion function after infection, compared the lung diffusion and ventilation function of children with mild (MMPP) or severe pneumonia (SMPP) infections, and explored their clinical significance.
Objective: To study the changes in pulmonary ventilation and pulmonary diffusion function in children with MPP, and explore their clinical significance.
Effect of nusinersen on pulmonary function in children with spinal muscular atrophy in the plateau region: A pilot study.
Heliyon
January 2025
Department of Pediatrics, The First People's Hospital of Yunnan Province, Medical School & Affiliated Hospital, Kunming University of Science and Technology, Kunming, Yunnan, China.
Background: The drug nusinersen is applied to improve motor function in patients with spinal muscle atrophy (SMA). However, research on the effects of this treatment on lung function is lacking.
Aim: To investigate the effect of nusinersen on lung function in children with SMA in the Plateau.
Lung function and onset of cardiometabolic diseases in the longitudinal Burden of Obstructive Lung Disease study.
BMJ Open Respir Res
January 2025
National Heart and Lung Institute, Imperial College London, London, UK.
Introduction: Previous population-based studies, mainly from high-income countries, have shown that a higher forced vital capacity (FVC) is associated with a lower risk of developing cardiometabolic diseases. The aim of this study was to assess the longitudinal association between spirometry measures and the onset of cardiometabolic diseases across sites in low-income, middle-income and high-income countries.
Methods: The study population comprised 5916 individuals from 15 countries participating in the Burden of Obstructive Lung Disease baseline and follow-up assessments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!